An immune-based biomarker signature is associated with mortality in COVID-19 patients
Open accessThe DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19). However, the utility of specific immune-based biomarkers to predict clinical outcome remains elusive. Here, we analyzed levels of 66 soluble biomarkers in 175 Italian patients with COVID-19 ranging from mild/moderate to critical severity and assessed type I IFN-, type II IFN-, and NF-κB-dependent whole-blood transcriptional signatures. A broad inflammatory signature was observed, implicating activation of various immune and nonhematopoietic cell subsets. Discordance between IFN-α2a protein and IFNA2 transcript levels in blood suggests that type I IFNs during COVID-19 may be primarily produced by tissue-resident cells. Multivariable analysis of patients' first samples revealed 12 biomarkers (CCL2, IL-15, soluble ST2 [sST2], NGAL, sTNFRSF1A, ferritin, IL-6, S100A9, MMP-9, IL-2, sVEGFR1, IL-10) that when increased were independently associated with mortality. Multivariate analyses of longitudinal biomarker trajectories identified 8 of the aforementioned biomarkers (IL-15, IL-2, NGAL, CCL2, MMP-9, sTNFRSF1A, sST2, IL-10) and 2 additional biomarkers (lactoferrin, CXCL9) that were substantially associated with mortality when increased, while IL-1α was associated with mortality when decreased. Among these, sST2, sTNFRSF1A, IL-10, and IL-15 were consistently higher throughout the hospitalization in patients who died versus those who recovered, suggesting that these biomarkers may provide an early warning of eventual disease outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · cited 3×
“Approximately one fourth of subjects hospitalized with COVID-19-associated pneumonia require respiratory support in an intensive care unit (ICU), and the need for invasive mechanical ventilation (IMV) has been associated with high mortality (3-5).”
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
mice: Multivariate Imputation by Chained Equations in R
Buuren, S. V., & Groothuis-Oudshoorn, K. (2011) · Journal of Statistical Software · doi:10.18637/jss.v045.i03 · Cited by 13,870 · cited 1×
“Missing data were imputed using multiple imputation by chained equations via the mice package in R (104).”
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,679
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254 · cited 2×
“Approximately one fourth of subjects hospitalized with COVID-19-associated pneumonia require respiratory support in an intensive care unit (ICU), and the need for invasive mechanical ventilation (IMV) has been associated with high mortality (3-5).”
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Mizgerd, J. P., Kubo, H., Kutkoski, G. J., Bhagwan, S. D., Scharffetter-Kochanek, K., Beaudet, A. L., & Doerschuk, C. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1357 · Cited by 7,306
(2010) · University of Twente Research Information · Cited by 6,037
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015432 · Cited by 5,613 · cited 1×
“Endothelial dysfunction is known to underlie several complications of infection (including thrombosis), which have been frequently observed in patients with COVID-19 (47).”
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984 · cited 4×
“The low transcriptional levels of IFNA2 detected in blood are consistent with decreased numbers of circulating plasmacytoid DCs (pDCs) and impaired production of type I IFN by circulating pDCs in COVID-19 patients reported by others (10, 16, 19).”
InfluentialAutoantibodies against type I IFNs in patients with life-threatening COVID-19
Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science · doi:10.1126/science.abd4585 · Cited by 2,662
Self-citationAn inflammatory cytokine signature predicts COVID-19 severity and survival
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1051-9 · Cited by 2,605 · cited 4×
“Consistent with some, but not all, prior studies (10, 14-16, 37, 38), TNF-α levels were increased in COVID-19 patients compared to HV, but levels did not differ among severity groups (Figure 1); in contrast, TNF-β levels were comparable between HV and COVID-19 patients (Supplementary Figure 4 and Supplementary Table 3…”
InfluentialPathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Merad, M., & Martin, J. C. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0331-4 · Cited by 2,472 · cited 1×
“Both virus-specific factors and host inflammatory responses have been implicated in determining disease severity and clinical outcome (7-9).”
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I. K. D., Hodeib, S., Korol, C., et al. (2020) · Science · doi:10.1126/science.abd4570 · Cited by 2,229 · cited 1×
“Although no correlation was observed between IFN-α2a levels and disease severity or risk of death in the patients analyzed in our study, we have evidence that impaired type I IFN production or signaling may contribute to aggravate the clinical phenotype of COVID-19 in patients with monogenic errors of type I IFN-media…”
Self-citationThe positive false discovery rate: a Bayesian interpretation and the q-value
Storey, J. D. (2003) · The Annals of Statistics · doi:10.1214/aos/1074290335 · Cited by 2,204
Longitudinal analyses reveal immunological misfiring in severe COVID-19
Lucas, C., Wong, P., Klein, J., Castro, T. B. R., Silva, J., Sundaram, M., Ellingson, M. K., Mao, T., Oh, J. E., Israelow, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2588-y · Cited by 2,074
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045 · cited 1×
“However, it is interesting to note that IL-10 inhibits expression of HLA class II molecules by antigen-presenting cells, a phenomenon that has been observed in myeloid cells of patients with severe COVID-19 (16, 40, 90, 91).”
Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., et al. (2020) · Science · doi:10.1126/science.abc8511 · Cited by 1,509
A single-cell atlas of the peripheral immune response in patients with severe COVID-19
Wilk, A. J., Rustagi, A., Zhao, N. Q., Roque, J., Martínez-Colón, G. J., McKechnie, J. L., Ivison, G. T., Ranganath, T., Vergara, R., Hollis, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0944-y · Cited by 1,493
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment
Schulte-Schrepping, J., Reusch, N., Paclik, D., Baßler, K., Schlickeiser, S., Zhang, B., Krämer, B., Krammer, T., Brumhard, S., Bonaguro, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.001 · Cited by 1,461 · cited 2×
“Activated neutrophils, including formation of neutrophil extracellular traps, have been implicated in the immunopathogenesis of severe COVID-19 (40-43).”
Wang, S., Song, R., Wang, Z., Jing, Z., Wang, S., & Ma, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01298 · Cited by 1,450
Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.007 · Cited by 1,419
Contribution of Neutrophils to Acute Lung Injury
Grommes, J., & Soehnlein, O. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00138 · Cited by 1,313
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272 · cited 1×
“Excessive inflammasome activation-mediated IL-1β and IL-18 production is also reflective of monocyte/macrophage activation and has been associated with cytokine release syndromes, viral and bacterial sepsis, and autoinflammatory conditions (28-30).”
Tocilizumab treatment in COVID‐19: A single center experience
Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., & Li, J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25801 · Cited by 1,237
Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans
Arunachalam, P. S., Wimmers, F., Mok, C. K. P., Perera, R. A. P. M., Scott, M., Hagan, T., Sigal, N., Feng, Y., Bristow, L., Tak-Yin Tsang, O., et al. (2020) · Science · doi:10.1126/science.abc6261 · Cited by 1,186 · cited 5×
“The low transcriptional levels of IFNA2 detected in blood are consistent with decreased numbers of circulating plasmacytoid DCs (pDCs) and impaired production of type I IFN by circulating pDCs in COVID-19 patients reported by others (10, 16, 19).”
InfluentialElevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
Herold, T., Jurinovic, V., Arnreich, C., Lipworth, B. J., Hellmuth, J. C., von Bergwelt-Baildon, M., Klein, M., & Weinberger, T. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.008 · Cited by 1,161
Chaudhry, A., Samstein, R. M., Treuting, P., Liang, Y., Pils, M. C., Heinrich, J.-M., Jack, R. S., Wunderlich, F. T., Brüning, J. C., Müller, W., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.018 · Cited by 980
A dynamic COVID-19 immune signature includes associations with poor prognosis
Laing, A. G., Lorenc, A., del Molino del Barrio, I., Das, A., Fish, M., Monin, L., Muñoz-Ruiz, M., McKenzie, D. R., Hayday, T. S., Francos-Quijorna, I., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1038-6 · Cited by 946 · cited 4×
“The low transcriptional levels of IFNA2 detected in blood are consistent with decreased numbers of circulating plasmacytoid DCs (pDCs) and impaired production of type I IFN by circulating pDCs in COVID-19 patients reported by others (10, 16, 19).”
InfluentialHeightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients
Zhou, Z., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.017 · Cited by 938
Facing Covid-19 in Italy — Ethics, Logistics, and Therapeutics on the Epidemic’s Front Line
Rosenbaum, L. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005492 · Cited by 881
Yang, Y., Shen, C., Li, J., Yuan, J., Wei, J., Huang, F., Wang, F., Li, G., Li, Y., Xing, L., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.027 · Cited by 872
Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867
Self-citationHow leukocytes cross the vascular endothelium
Vestweber, D. (2015) · Nature Reviews Immunology · doi:10.1038/nri3908 · Cited by 858 · cited 1×
“17 Leukocyte migration from the bloodstream to infected tissues requires their highly coordinated interaction with the endothelial surface (46).”
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19
Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A.-G., Dubuisson, A., Derosa, L., Almire, C., Hénon, C., Kosmider, O., Droin, N., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.002 · Cited by 834
Lee, J. S., Park, S., Jeong, H. W., Ahn, J. Y., Choi, S. J., Lee, H., Choi, B., Nam, S. K., Sa, M., Kwon, J.-S., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd1554 · Cited by 825
Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency
Dupuis, S., Jouanguy, E., Al-Hajjar, S., Fieschi, C., Al-Mohsen, I. Z., Al-Jumaah, S., Yang, K., Chapgier, A., Eidenschenk, C., Eid, P., et al. (2003) · Nature Genetics · doi:10.1038/ng1097 · Cited by 816
Skendros, P., Mitsios, A., Chrysanthopoulou, A., Mastellos, D. C., Metallidis, S., Rafailidis, P., Ntinopoulou, M., Sertaridou, E., Tsironidou, V., Tsigalou, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci141374 · Cited by 786
Glucocorticoids and invasive fungal infections
Lionakis, M. S., & Kontoyiannis, D. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14904-5 · Cited by 669
Self-citationAnakinra for severe forms of COVID-19: a cohort study
Huet, T., Beaussier, H., Voisin, O., Jouveshomme, S., Dauriat, G., Lazareth, I., Sacco, E., Naccache, J.-M., Bézie, Y., Laplanche, S., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30164-8 · Cited by 643
Predictors of mortality in hospitalized COVID‐19 patients: A systematic review and meta‐analysis
Tian, W., Jiang, W., Yao, J., Nicholson, C. J., Li, R. H., Sigurslid, H. H., Wooster, L., Rotter, J. I., Guo, X., & Malhotra, R. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26050 · Cited by 640
The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases
Griesenauer, B., & Paczesny, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00475 · Cited by 619
IRF8 Mutations and Human Dendritic-Cell Immunodeficiency
Hambleton, S., Salem, S., Bustamante, J., Bigley, V., Boisson-Dupuis, S., Azevedo, J., Fortin, A., Haniffa, M., Ceron-Gutierrez, L., Bacon, C. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100066 · Cited by 598
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent
Mazzoni, A., Salvati, L., Maggi, L., Capone, M., Vanni, A., Spinicci, M., Mencarini, J., Caporale, R., Peruzzi, B., Antonelli, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138554 · Cited by 502
Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection
Alves-Filho, J. C., Sônego, F., Souto, F. O., Freitas, A., Verri, W. A., Auxiliadora-Martins, M., Basile-Filho, A., McKenzie, A. N., Xu, D., Cunha, F. Q., et al. (2010) · Nature Medicine · doi:10.1038/nm.2156 · Cited by 486
Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency
Ciancanelli, M. J., Huang, S. X. L., Luthra, P., Garner, H., Itan, Y., Volpi, S., Lafaille, F. G., Trouillet, C., Schmolke, M., Albrecht, R. A., et al. (2015) · Science · doi:10.1126/science.aaa1578 · Cited by 476
Self-citationBurbelo, P. D., Riedo, F. X., Morishima, C., Rawlings, S., Smith, D., Das, S., Strich, J. R., Chertow, D. S., Davey, R. T., & Cohen, J. I. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa273 · Cited by 471
Self-citationBasic Concepts and Methods for Joint Models of Longitudinal and Survival Data
Ibrahim, J. G., Chu, H., & Chen, L. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0654 · Cited by 460
Gong, J., Dong, H., Xia, Q.-S., Huang, Z.-Y., Wang, D.-K., Zhao, Y., Liu, W.-H., Tu, S.-H., Zhang, M.-M., Wang, Q., et al. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05681-5 · Cited by 435
Zhao, Y., Qin, L., Zhang, P., Li, K., Liang, L., Sun, J., Xu, B., Dai, Y., Li, X., Zhang, C., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.139834 · Cited by 408
Type 1 and Type 2 Cytokine Imbalance in Acute Respiratory Syncytial Virus Bronchiolitis
Legg, J. P., Hussain, I. R., Warner, J. A., Johnston, S. L., & Warner, J. O. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200210-1148oc · Cited by 390
The γc Family of Cytokines: Basic Biology to Therapeutic Ramifications
Leonard, W. J., Lin, J.-X., & O'Shea, J. J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.028 · Cited by 383
Zhang, D., Guo, R., Lei, L., Liu, H., Wang, Y., Wang, Y., Qian, H., Dai, T., Zhang, T., Lai, Y., et al. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.4hi0720-470r · Cited by 383
van der Sluijs, K. F., van Elden, L. J. R., Nijhuis, M., Schuurman, R., Pater, J. M., Florquin, S., Goldman, M., Jansen, H. M., Lutter, R., & van der Poll, T. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7603 · Cited by 334
Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis
Wilson, J. G., Simpson, L. J., Ferreira, A.-M., Rustagi, A., Roque, J., Asuni, A., Ranganath, T., Grant, P. M., Subramanian, A., Rosenberg-Hasson, Y., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140289 · Cited by 256
Elshazli, R. M., Toraih, E. A., Elgaml, A., El-Mowafy, M., El-Mesery, M., Amin, M. N., Hussein, M. H., Killackey, M. T., Fawzy, M. S., & Kandil, E. (2020) · PLOS ONE · doi:10.1371/journal.pone.0238160 · Cited by 253
Dimopoulos, G., de Mast, Q., Markou, N., Theodorakopoulou, M., Komnos, A., Mouktaroudi, M., Netea, M. G., Spyridopoulos, T., Verheggen, R. J., Hoogerwerf, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.007 · Cited by 245
Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19
Mann, E. R., Menon, M., Knight, S. B., Konkel, J. E., Jagger, C., Shaw, T. N., Krishnan, S., Rattray, M., Ustianowski, A., Bakerly, N. D., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd6197 · Cited by 241
Human IFNAR2 deficiency: Lessons for antiviral immunity
Duncan, C. J. A., Mohamad, S. M. B., Young, D. F., Skelton, A. J., Leahy, T. R., Munday, D. C., Butler, K. M., Morfopoulou, S., Brown, J. R., Hubank, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4227 · Cited by 237
Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency
Hernandez, N., Melki, I., Jing, H., Habib, T., Huang, S. S. Y., Danielson, J., Kula, T., Drutman, S., Belkaya, S., Rattina, V., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180628 · Cited by 210
Self-citationJoyce, D. A., Gibbons, D. P., Green, P., Steer, J. H., Feldmann, M., & Brennan, F. M. (1994) · European Journal of Immunology · doi:10.1002/eji.1830241119 · Cited by 206
IL-6–based mortality risk model for hospitalized patients with COVID-19
Laguna-Goya, R., Utrero-Rico, A., Talayero, P., Lasa-Lazaro, M., Ramirez-Fernandez, A., Naranjo, L., Segura-Tudela, A., Cabrera-Marante, O., Rodriguez de Frias, E., Garcia-Garcia, R., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.009 · Cited by 204
Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency
Walter, J. E., Rosen, L. B., Csomos, K., Rosenberg, J. M., Mathew, D., Keszei, M., Ujhazi, B., Chen, K., Lee, Y. N., Tirosh, I., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80477 · Cited by 202
Self-citationImmune regulation by glucocorticoids can be linked to cell type–dependent transcriptional responses
Franco, L. M., Gadkari, M., Howe, K. N., Sun, J., Kardava, L., Kumar, P., Kumari, S., Hu, Z., Fraser, I. D. C., Moir, S., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180595 · Cited by 194
Self-citationSevere influenza pneumonitis in children with inherited TLR3 deficiency
Lim, H. K., Huang, S. X. L., Chen, J., Kerner, G., Gilliaux, O., Bastard, P., Dobbs, K., Hernandez, N., Goudin, N., Hasek, M. L., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181621 · Cited by 194
Self-citationDevelopment of a Validated Interferon Score Using NanoString Technology
Kim, H., de Jesus, A. A., Brooks, S. R., Liu, Y., Huang, Y., VanTries, R., Montealegre Sanchez, G. A., Rotman, Y., Gadina, M., & Goldbach-Mansky, R. (2018) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2017.0127 · Cited by 190
Self-citationHernandez, N., Bucciol, G., Moens, L., Le Pen, J., Shahrooei, M., Goudouris, E., Shirkani, A., Changi-Ashtiani, M., Rokni-Zadeh, H., Sayar, E. H., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182295 · Cited by 179
Piktel, E., Levental, I., Durnaś, B., Janmey, P. A., & Bucki, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092516 · Cited by 160
Neutrophil calprotectin identifies severe pulmonary disease in COVID-19
Shi, H., Zuo, Y., Yalavarthi, S., Gockman, K., Zuo, M., Madison, J. A., Blair, C., Woodard, W., Lezak, S. P., Lugogo, N. L., et al. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3covcra0720-359r · Cited by 159
Increased IL-33 expression in chronic obstructive pulmonary disease
Xia, J., Zhao, J., Shang, J., Li, M., Zeng, Z., Zhao, J., Wang, J., Xu, Y., & Xie, J. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00305.2014 · Cited by 153
Self-Awareness: Nucleic Acid–Driven Inflammation and the Type I Interferonopathies
Uggenti, C., Lepelley, A., & Crow, Y. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041257 · Cited by 150
Soluble ST2 plasma concentrations predict mortality in severe sepsis
Hoogerwerf, J. J., Tanck, M. W. T., van Zoelen, M. A. D., Wittebole, X., Laterre, P., & van der Poll, T. (2010) · Intensive Care Medicine · doi:10.1007/s00134-010-1773-0 · Cited by 131
Interleukin-33 activates regulatory T cells to suppress innate γδ T cell responses in the lung
Faustino, L., Griffith, J. W., Rahimi, R. A., Nepal, K., Hamilos, D. L., Cho, J. L., Medoff, B. D., Moon, J. J., Vignali, D. A. A., & Luster, A. D. (2020) · Nature Immunology · doi:10.1038/s41590-020-0785-3 · Cited by 128
Negative regulation of MyD88-dependent signaling by IL-10 in dendritic cells
Chang, J., Kunkel, S. L., & Chang, C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905815106 · Cited by 125
Dickensheets, H. L., Freeman, S. L., Smith, M. F., & Donnelly, R. P. (1997) · Blood · doi:10.1182/blood.v90.10.4162 · Cited by 107
Characteristics of Autoantibodies to Human Interferon in a Patient with Varicella-Zoster Disease
Pozzetto, B., Mogensen, K. E., Tovey, M. G., & Gresser, I. (1984) · The Journal of Infectious Diseases · doi:10.1093/infdis/150.5.707 · Cited by 104
Dubois, C., Marcé, D., Faivre, V., Lukaszewicz, A., Junot, C., Fenaille, F., Simon, S., Bécher, F., Morel, N., & Payen, D. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-52184-8 · Cited by 90
Moving towards a systems-based classification of innate immune-mediated diseases
Savic, S., Caseley, E. A., & McDermott, M. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0377-5 · Cited by 90
Increased IL‐10‐producing regulatory T cells are characteristic of severe cases of COVID‐19
Neumann, J., Prezzemolo, T., Vanderbeke, L., Roca, C. P., Gerbaux, M., Janssens, S., Willemsen, M., Burton, O. T., Mol, P. V., Herck, Y. V., et al. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1204 · Cited by 90
Monocyte CD169 Expression as a Biomarker in the Early Diagnosis of Coronavirus Disease 2019
Bedin, A., Makinson, A., Picot, M., Mennechet, F. J. D., Malergue, F., Pisoni, A., Nyiramigisha, E., Montagnier, L., Bolloré, K., Debiesse, S., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa724 · Cited by 88
Bedoya, F., Cheng, G., Leibow, A., Zakhary, N., Weissler, K. A., Garcia, V., Aitken, M., Kropf, E., Garlick, D. S., Wherry, E. J., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203302 · Cited by 86
Vultaggio, A., Vivarelli, E., Virgili, G., Lucenteforte, E., Bartoloni, A., Nozzoli, C., Morettini, A., Berni, A., Malandrino, D., Rossi, O., et al. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.06.013 · Cited by 74
Pregernig, A., Müller, M. M., Held, U., & Beck‐Schimmer, B. (2019) · Annals of Intensive Care · doi:10.1186/s13613-019-0600-1 · Cited by 61
IL-15 immunotherapy is a viable strategy for COVID-19
Kandikattu, H. K., Venkateshaiah, S. U., Kumar, S., & Mishra, A. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.008 · Cited by 61
Zhang, A. W., Morjaria, S. M., Kaltsas, A., Hohl, T. M., Parameswaran, R., Patel, D. M., Zhou, W., Predmore, J., Pérez-Johnston, R., Jee, J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab534 · Cited by 54
Interleukin-15 and its impact on neutrophil function
Cassatella, M. A., & McDonald, P. P. (2000) · Current Opinion in Hematology · doi:10.1097/00062752-200005000-00008 · Cited by 49
Flow Cytometry Identifies Risk Factors and Dynamic Changes in Patients with COVID-19
Moratto, D., Chiarini, M., Giustini, V., Serana, F., Magro, P., Roccaro, A. M., Imberti, L., Castelli, F., Notarangelo, L. D., & Quirós-Roldán, E. (2020) · Journal of Clinical Immunology · doi:10.1007/s10875-020-00806-6 · Cited by 48
Self-citationChen, K., Chaou, C., Jiang, J., Yu, H.-W., Meng, Y.-H., Tang, W.-C., & Wu, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153188 · Cited by 45
Perlin, D. S., Zafir‐Lavie, I., Roadcap, L., Raines, S. R., Ware, C. F., & Neil, G. A. (2020) · mSphere · doi:10.1128/msphere.00699-20 · Cited by 40
Arbeev, K. G., Akushevich, I. V., Kulminski, A. M., Ukraintseva, S. V., & Yashin, A. I. (2014) · Frontiers in Public Health · doi:10.3389/fpubh.2014.00228 · Cited by 26
Outcome of COVID-19 patients with use of Tocilizumab: A single center experience
Mushtaq, M. Z., Mahmood, S. B. Z., Jamil, B., Aziz, A., & Ali, S. A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106926 · Cited by 24
Agouridakis, P., Kyriakou, D. S., Alexandrakis, M. G., Perisinakis, K., Karkavitsas, N., & Bouros, D. E. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.01081.x · Cited by 22
Cited by
Immune Senescence, Immunosenescence and Aging
Lee, K.-A., Flores, R. R., Jang, I. H., Saathoff, A., & Robbins, P. D. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.900028 · Cited by 283
Sacco, K., Castagnoli, R., Vakkilainen, S., Liu, C., Delmonte, O. M., Oguz, C., Kaplan, I. M., Alehashemi, S., Burbelo, P. D., Bhuyan, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01724-3 · Cited by 247
Self-citationBiomarkers of post-covid depression
Lorkiewicz, P., & Waszkiewicz, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184142 · Cited by 102
Metadata
- Authors
- Abers, M. S., Delmonte, O. M., Ricotta, E. E., Fintzi, J., Fink, D. L., de Jesus, A. A. A., Zarember, K. A., Alehashemi, S., Oikonomou, V., Desai, J. V., Canna, S. W., Shakoory, B., Dobbs, K., Imberti, L., Sottini, A., Quiros-Roldan, E., Castelli, F., Rossi, C., Brugnoni, D., Biondi, A., Bettini, L. R., D’Angio’, M., Bonfanti, P., Castagnoli, R., Montagna, D., Licari, A., Marseglia, G. L., Gliniewicz, E. F., Shaw, E., Kahle, D. E., Rastegar, A. T., Stack, M., Myint-Hpu, K., Levinson, S. L., DiNubile, M. J., Chertow, D. W., Burbelo, P. D., Cohen, J. I., Calvo, K. R., Tsang, J. S., Su, H. C., Gallin, J. I., Kuhns, D. B., Goldbach-Mansky, R., Lionakis, M. S., & Notarangelo, L. D.
- Venue
- JCI Insight
- Published
- 2021-01-11
- Volume
- 6
- Issue
- 1
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W3107765474
- Cited by
- 340
- References
- 98
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.